John Parkinson is the assistant managing editor for Contagion. Prior to joining MJH Life Sciences in 2020, he has covered a variety of fields and markets including diabetes, oncology, ophthalmology, IT, travel, and local news. You can email him at jparkinson@mjhlifesciences.com.
With the Rise of COVID-19 Vaccines, a Greater Public Mistrust of Immunizations Has Taken Hold
March 25th 2025In the second installment of our COVID-19 pandemic series, Robert Hopkins Jr, MD, the medical director of the National Foundation for Infectious Diseases (NFID), discusses the paradox that has arisen from the COVID-19 vaccines that in spite of their development in record time, what remains is a deeper mistrust in immunizations overall.
Read More
A Late-Stage Tuberculosis Vaccine is Making its Way Through Clinical Trials
March 23rd 2025Monday is World Tuberculosis (TB) Day, and a vaccine developed by the Gates Medical Research Institute is being studied in a phase 3 trial. If approved, the vaccine could potentially prevent pulmonary TB in adults and adolescents.
Read More
The COVID-19 Pandemic: Significance of Screening and Industry's Response
March 20th 2025This is the first in a series on the 5 year anniversary of the pandemic. We want to cover a variety of aspects around it, including lessons learned such as testing, vaccine development, and public health policy as well as some ongoing challenges that remain including vaccine hesitancy and an increase in antimicrobial resistant infections.
Read More
CDC: Hospitals Experiencing Inconsistent Declines in Resistant Infections
March 20th 2025A long-term study conducted by the Centers for Disease Control and Prevention (CDC) shows early success in the reduction of such infections followed by an increase again during the early pandemic years. Additionally, certain pathogens overall saw an increase, whereas other infections were stable or saw decreases.
Read More
Fear, Misconceptions Discourage International Hepatitis B and C Testing
March 18th 2025Despite a large number of new infections globally, an international survey shows real reservations by people to get screened and limited knowledge about the risks, thus preventing them from seeking needed treatment.
Read More
The Case for HIV Prevention and Screening: Pay Today or Pay Tomorrow
March 16th 2025Carl Schmid, executive director, HIV + Hepatitis Policy Institute, explains how a Supreme Court case could have far reaching implications for greater health screenings and preventative services beyond HIV and hepatitis.
Read More
Apretude PrEP Shows High Efficacy, Safety in Diverse Studies
March 14th 2025New data at CROI 2025 shows zero cases of HIV acquisition reported with Apretude (cabotegravir long-acting (CAB LA) for PrEP in varied clinical settings and populations in 2 implementation studies in the US and Brazil.
Read More
HIV Prevention: Discussing PrEP, PEP, and Vaccine Development
March 13th 2025Colleen Kelley, MD, MPH, offers some insights on where we are today with the state of HIV prevention including the expanding PrEP options, why PEP is underutilized, and the challenges behind HIV vaccine development.
Read More
Doravirine and Islatravir Combination Shown to be Noninferior to Once-Daily ART
March 12th 2025In a blinded phase 3 study, doravirine and islatravir was compared to antiretroviral therapy, BIC/FTC/TAF (Biktarvy), and it was shown that there was no between-group differences in mean change in CD4 T-cell or total lymphocyte count at week 48.
Read More
Cautionary Tale Associated in Trial With Rare Error in Cox Regression
March 6th 2025InflaRx CEO Niels Riedemann, MD, discusses the issue that arose and cost the company some of its data for its investigational therapy being studied for SARS-CoV-2-induced acute respiratory distress syndrome (ARDS).
Read More
Synthetic Gel Shows Utility Across ABSSSI, Company Sees Other Indications
March 4th 2025Alan Dunton, MD, director and chief medical advisor, Recce Pharmaceuticals, discusses the company’s novel product, R327G (RECCE 327), and offers insights into its potential indications and clinical trials.
Read More
WHO Releases 2025-2026 Influenza Vaccine Recommendations
February 28th 2025With the release of these guidelines and the US Health and Human Services canceling the mid-March FDA VRBPAC meeting to discuss these vaccine recommendations, Robert Hopkins Jr, MD, the medical director of the National Foundation for Infectious Diseases (NFID), offers insight on these developments.
Read More